Finch Therapeutics Group (NASDAQ: FNCH)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | ||||||
REV | 354.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Finch Therapeutics Group (NASDAQ: FNCH) through any online brokerage.
Other companies in Finch Therapeutics Group’s space includes: CytomX Therapeutics (NASDAQ:CTMX), Celcuity (NASDAQ:CELC), Immuneering (NASDAQ:IMRX), Fusion Pharmaceuticals (NASDAQ:FUSN) and Gelesis Holdings (NYSE:GLS).
The latest price target for Finch Therapeutics Group (NASDAQ: FNCH) was reported by Jefferies on Monday, April 4, 2022. The analyst firm set a price target for 17.00 expecting FNCH to rise to within 12 months (a possible 511.51% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Finch Therapeutics Group (NASDAQ: FNCH) is $2.78 last updated June 28, 2022, 8:00 PM UTC.
There are no upcoming dividends for Finch Therapeutics Group.
Finch Therapeutics Group’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Finch Therapeutics Group.
Finch Therapeutics Group is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.